Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2022

Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial

In patients with acute myocardial infarction, adding biweekly alirocumab to high-intensity statin therapy led to greater regression of coronary atherosclerosis and improved plaque stability markers compared to placebo. The PACMAN-AMI trial used serial multimodality intracoronary imaging to show significant benefits on plaque burden, lipid content, and fibrous cap thickness.
Lorenz Räber; Y. Ueki; T. Otsuka; S. Losdat; J. Häner; J. Lønborg; G. Fahrni; J. Iglesias; R. van Geuns; A. Ondracek; Maria D. Radu Juul Jensen; C. Zanchin; S. Stortecky; D. Spirk; G. Siontis; L. Saleh; C. Matter; J. Daemen; F. Mach; D. Heg; S. Windecker; T. Engstrøm; I. Lang; K. Koskinas; Maria Ambühl; Sarah Bär; André Frenk; Laura U. Morf; Andrea Inderkum; Stefanie Leuthard; Raminta Kavaliauskaite; Emrush Rexhaj; Hiroki Shibutani; Vera R. Mitter; Christoph Kaiser; Manuel Mayr; Franz R. Eberli; Crochan J. O'Sullivan; Christian Templin; Arnold von Eckardstein; Art Ghandilyan; Ravindra Pawar; Hans Jonker; Thomas Hofbauer; Georg Goliasch; Lia Bang; Rikke Sørensen; Maria N. Tovar Forero; Sophie Degrauwe; Tim Ten Cate· Journal of the American Medical Association (JAMA)· 2022· DOI 10.1001/jama.2022.5218

The core problem

Coronary plaques prone to rupture and causing adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown. The PACMAN-AMI trial aimed to determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction (AMI).

Innovation

The PACMAN-AMI trial was a double-blind, placebo-controlled, randomized clinical trial conducted at 9 academic European hospitals. Enrollment occurred from May 9, 2017, through October 7, 2020, with final follow-up on October 13, 2021. A total of 300 patients undergoing percutaneous coronary intervention (PCI) for AMI were randomized to receive biweekly subcutaneous alirocumab (150 mg; n=148) or placebo (n=152), initiated less than 24 hours after urgent PCI of the culprit lesion, for 52 weeks in addition to high-intensity statin therapy (rosuvastatin 20 mg).

Intravascular ultrasonography (IVUS), near-infrared spectroscopy (NIRS), and optical coherence tomography (OCT) were serially performed in the 2 non-infarct-related coronary arteries at baseline and after 52 weeks. The primary efficacy end point was the change in IVUS-derived percent atheroma volume (PAV) from baseline to week 52. Two powered secondary end points were changes in NIRS-derived maximum lipid core burden index within 4 mm (maxLCBI4mm; higher values indicating greater lipid content) and OCT-derived minimal fibrous cap thickness (minFCT; smaller values indicating thin-capped, vulnerable plaques) from baseline to week 52.

Introduction
Coronary plaques prone to rupture and causing adverse cardiac events are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, the effect of the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab added to statin therapy on plaque burden and composition remains largely unknown. The PACMAN-AMI trial aimed to determine the effects of alirocumab on coronary atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction (AMI).

Why it matters

The PACMAN-AMI trial demonstrates that in patients with AMI, the addition of subcutaneous biweekly alirocumab to high-intensity statin therapy results in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks. The beneficial effects were consistent across all three imaging modalities: IVUS showed a greater reduction in percent atheroma volume, NIRS indicated a larger decrease in lipid core burden, and OCT revealed a greater increase in fibrous cap thickness, suggesting enhanced plaque stability. These findings support the concept that intensive LDL-C lowering with PCSK9 inhibitors beyond statin therapy can modulate plaque composition and potentially reduce future cardiovascular events. However, the study was not powered for clinical outcomes, and further research is needed to determine whether these imaging improvements translate into reduced cardiovascular morbidity and mortality. The safety profile was comparable between groups, with similar rates of adverse events.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…